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The  efﬁcacy  and safety  of a novel  isoxazoline  parasiticide,  sarolaner  (SimparicaTM),  for  the  control  of  ﬂeas
on  dogs  was  evaluated  in  a randomized,  controlled  clinical  study  conducted  in 19 general  veterinary
practices  throughout  the  United  States.  Four  hundred  and  seventy  nine  (479)  dogs  from  293  households
were  enrolled.  Each  household  was  randomly  assigned  to  treatment  with  either  sarolaner  oral  tablets
(SimparicaTM, Zoetis)  at the  proposed  label  dose  or an  approved  comparator  product  at  the  label  dose
(spinosad,  Comfortis®, Elanco).  Dogs  were  dosed  by  their  owners  at home  on  Day  0  and  on approximately
Days  30  and  60. Dogs  were  examined  at the clinics  for general  health,  ﬂea  and  tick  infestation,  and  clinical
signs  of ﬂea  allergy  dermatitis  (FAD)  at the  initial  visit  and  Days  14, 30,  60 and  90.  Blood was  collected
for  clinical  pathology  at screening  and  Day  90.
Sarolaner  was  well-accepted  by dogs  with  the  majority  of  ﬂavored  chewable  tablets  (91.5%)  accepted
free  choice,  by hand  or in  food.  Geometric  mean  live  ﬂea  counts  were  reduced  by  >99%  at  the  ﬁrst  time
measured  (14 days)  after  initiation  of  treatment  and  continued  to  reduce  through  the study.  Treatment
success  (proportion  of dogs  with  ≥90%  reduction  in ﬂeas)  for the  sarolaner-treated  dogs  was  superior  to
that for spinosad-treated  dogs  at Days  14  and  30 and  non-inferior  on Days  60 and  90 (P ≤  0.025)  The  rapid
reduction  in ﬂea  infestations  resulted  in a similar  rapid  resolution  of  the  clinical  signs  associated  with  FAD.
Sarolaner  chewable  tablets  were  well  tolerated  with  no  treatment  related  adverse  reactions.  Most  of the
clinical  signs  reported  were  consistent  with  allergies  and  dermatitis  or sporadic  occurrences  of conditions
commonly  observed  in  the general  dog  population.  A  wide  variety  of concomitant  medications,  including
many  commercially  available  heartworm  preventatives  and  other  anthelmintic  drugs,  were  administered
to  study  dogs  and  all  were  well  tolerated.
Sarolaner administered  orally  to  provide  a minimum  dosage  of  2.0  mg/kg  (range  2–4 mg/kg)  once
monthly  for  three  consecutive  treatments  was  safe  and  effective  in  the  treatment  and  prevention  of
natural  infestations  of  ﬂeas  and resulted  in a substantial  improvement  of  clinical  signs  associated  with
FAD.
© 2016  Published  by Elsevier  B.V. This  is an  open  access  article  under the  CC  BY-NC-ND  license. Introduction
The cat ﬂea, Ctenocephalides felis felis is one of the most impor-
ant ectoparasites of dogs and cats worldwide (Rust and Dryden,
997). Prevention and control of ﬂeas is a cornerstone of preventive
eterinary medicine and effective ﬂea control relies on fast onset of
ction, consistent coverage over the dosing interval, and pet owner
ompliance. Adult ﬂeas are blood feeders and create local irrita-
ion caused by feeding and heavy infestations can lead to anemia.
leas are intermediate hosts for the dog tapeworm and transmit a
umber of diseases including zoonoses, and in the absence of pri-
∗ Corresponding author.
E-mail address: robert.six@zoetis.com (R.H. Six).
ttp://dx.doi.org/10.1016/j.vetpar.2015.12.022
304-4017/© 2016 Published by Elsevier B.V. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/4.0/).
mary hosts will readily feed on humans (Dryden, 1989; Krämer and
Menke, 2001). In general, the clinical signs associated with ﬂea bites
(ﬂea bite dermatitis), including pruritus, papules, erythema, scal-
ing, alopecia and dermatitis/pyodermatitis, are transient. However,
in some dogs, exposure to ﬂeas may  lead to a more serious condition
of ﬂea allergy dermatitis (FAD) which is the most common derma-
tologic disease of domestic dogs (Dryden, 2009). In the FAD dog,
once sensitization has occurred, recurrence of signs can be initiated
by just a small number of bites, although the threshold of sensitivity
varies between individual dogs (Carlotti and Jacobs, 2000). Success-
ful management of the FAD case ultimately depends on eliminating
ﬂeas as they are the source of allergenic challenge, and year-round
prevention of ﬂea infestations is recommended (Olivry et al., 2010).
Although commercial products for the prevention of ﬂea infesta-
tions are available to veterinarians and pet owners, there remains
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pportunity to provide new options which could improve speed of
ill, consistency of coverage and client compliance.
Sarolaner is a novel parasiticide belonging to the isoxazoline
lass. Laboratory studies have conﬁrmed that a minimum sarolaner
ose of 2 mg/kg begins killing ﬂeas three hours after treatment
nd is highly effective for the treatment and control of existing
at ﬂea infestations and the persistent control of ﬂeas on dogs for
5 days after treatment (Six et al., 2016a,b). Here, we  report on a
linical ﬁeld study conducted to evaluate the efﬁcacy and safety of
arolaner (SimparicaTM, Zoetis) ﬂavored, chewable tablets admin-
stered orally for three months at a minimum dosage of 2.0 mg/kg
range–4 mg/kg) compared to spinosad oral tablets (Comfortis®,
lanco) administered per label for the treatment and prevention
f natural ﬂea infestations in client-owned dogs.
. Materials and methods
The study was  conducted in accordance with the World Asso-
iation for the Advancement of Veterinary Parasitology (WAAVP)
uidelines for evaluating the efﬁcacy of parasiticides for the treat-
ent, prevention and control of ﬂea and tick infestation on dogs
nd cats (Marchiondo et al., 2013) and complied with Good Clinical
ractices (EMEA, 2000). The protocol was reviewed and approved
y the Zoetis Institutional Animal Care and Use Committee.
.1. Animals
The patient population was recruited from veterinary practices
ocated in various geographical regions of the United States, rep-
esenting the range of typical clients for North America. Patients
ame from diverse households and living conditions, thus dogs
ived indoors only, outdoors only, or both indoors and outdoors.
ogs came from single dog households and households with other
ogs (up to a total of three dogs) and/or cats. There were no breed
r gender restrictions, but dogs intended for breeding or that were
regnant or lactating were not eligible for enrollment. For inclu-
ion in the study at least one dog in the household had to harbor at
east 10 ﬂeas. Dogs had to be at least 8 weeks of age and weigh at
east 1.25 kg. Dogs less than 14 weeks of age and allocated to the
pinosad treatment group were excluded from enrollment in order
o comply with the Comfortis® label requirements. Dogs with pre-
xisting conditions under stable veterinary management could be
ncluded as could dogs with clinical signs of ﬂea infestation. Dogs
ith existing uncontrolled medical conditions that might confound
he study were excluded. Dogs could not have been treated with any
roducts with residual activity against ﬂeas within 30 days or any
hort-acting ectoparasiticide within 7 days of the start of the study.
.2. Experimental design and methods
The study was a single-masked, positively-controlled clinical
rial with a randomized complete block design. For a household
o be included, at least one dog had to have 10 or more live ﬂeas.
here more than one dog met  this criterion, a primary dog was
andomly selected, and the other dogs were designated as supple-
entary dogs. All dogs in a household received the same treatment
s the primary dog and were included in safety evaluations. Only
rimary dogs were included in the efﬁcacy evaluations. Households
ere allocated randomly to treatment with sarolaner or spinosad
n a ratio of 2:1 based on the order of enrollment. Dogs were
oused and maintained under their normal home conditions for the
uration of the study. Other than the experimental treatments, no
roducts (systemic, premise, and/or over-the-counter treatments
ncluding insecticidal shampoos or collars) that had activity against
eas were permitted to be used on any animal in the household forsitology 222 (2016) 43–48
the duration of the study. Non-insecticidal shampoos were permit-
ted to be used; however primary dogs could not be bathed within
three days of an assessment. The use of corticosteroids was  permit-
ted, but dogs that received corticosteroids during the study were
excluded from the skin assessment analysis.
Eligibility for inclusion in the study was determined at the ini-
tial screening visit. Dogs were weighed, given a physical exam,
had blood collected for hematology and blood chemistry testing,
and had urine collected for urinalysis to assess general health. Flea
counts were conducted by personnel trained to a standardized
methodology. The dogs were thoroughly ﬂea-combed using a com-
mercial ﬁne tooth ﬂea comb to remove and count ﬂeas. Dogs were
systematically combed while standing starting from the head, then
proceeding caudally along the dorsum. The dog was  then placed
on each side and then on its back for combing of the sides and
ventral surfaces. Dogs were repeatedly combed until no ﬂeas were
recovered within a 5 min  period. Each dog was  examined for a
minimum of 10 min. Fleas maintaining an upright orientation/or
moving in a coordinated manner were considered to be live. Only
live ﬂea counts were recorded. Any ticks, live or dead, removed dur-
ing the ﬂea-combing process, were placed into two appropriately
marked containers. After combing was  completed, the dog’s body
was examined, using the thumb and foreﬁngers, for any remaining
ticks which were removed and placed in the appropriately marked
containers. Ticks showing movement and responding to external
stimuli were considered to be live. The ticks collected were sub-
mitted to a parasitologist for identiﬁcation of species, sex, stage,
and engorgement status. All personnel conducting observations or
animal care, or performing the ﬂea and tick counts were masked to
treatment allocation.
All dogs in multi-dog households underwent these screening
exams. The primary dog was identiﬁed and evaluated by the vet-
erinarian for the presence and severity of the following clinical
signs: pruritus, papules, erythema, scaling, alopecia, and dermati-
tis/pyodermatitis. Flea allergy dermatitis was diagnosed on the
basis of the dog’s history, the presence of these clincial signs, and
the improvement in these signs at the completion of ﬂea treatment
(Daigle, 2005; Grifﬁn, 2010; Ihrke, 2008).
If at the initial visit, a tick control product was requested or rec-
ommended, a placebo collar was  dispensed for sarolaner-treated
dogs or an amitraz containing collar (Preventic®, Virbac) was  dis-
pensed to dogs to be treated with spinosad. On subsequent visits, if
tick control was requested or recommended, amitraz collars were
dispensed to dogs in either treatment group. For households with
cats, the use of a commercially available ﬂea treatment in those
animals was encouraged.
Eligible households were randomly allocated to treatment with
either sarolaner or spinosad oral tablets on order of presentation to
the clinic. Sarolaner tablets were provided in six different strengths
to provide a minimum dosage of 2.0 mg/kg (range 2–4 mg/kg).
Spinosad tablets were dispensed per label directions to provide a
dose ≥30 mg  spinosad/kg. Owners were provided with sarolaner
and spinosad at the clinic, and then administered treatments and
evaluated product consumption at home for all dogs in the house-
hold. Day 0 was deﬁned as the day on which the primary dog
received its ﬁrst dose. All animals enrolled within the household
were treated on the same day, and within one day of the clinic visit.
The dose was  offered or given at any time of the day. There were no
restrictions regarding the prandial state at the time of sarolaner
administration, therefore tablets could be administered with or
without food. Spinosad was administered with the main meal of
the dog in order to comply with the approved dosing directions
for that product. In order to assess tablet palatability, owners were
instructed to ﬁrst offer the tablet(s) without food. If the tablet(s)
were not consumed directly, then they were to be offered in a small
amount of food. If the tablet(s) were not consumed with food, then
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Table  1
Clinic location and number and percentage of dogs enrolled in a clinical ﬁeld study to investigate the efﬁcacy and safety of sarolaner tablets administered orally once a month
for  three months for the treatment and control of ﬂeas in dogs presented as veterinary patients in the USA.
Clinic location Primary dogs (efﬁcacy) All dogs (safety)
Sarolaner Spinosad Total Sarolaner Spinosad Total
n % n % n % n % n % n %
Lake Worth, FL 10 5.1 5 5.1 15 5.1 17 5.4 10 6.1 27 5.6
Bradenton, FL 3 1.5 1 1.0 4 1.4 5 1.6 2 1.2 7 1.5
Savannah, GA 24 12.3 12 12.3 36 12.3 45 14.3 16 9.8 61 12.7
New  Braunfels, TX 8 4.1 3 3.1 11 3.8 16 5.1 8 4.9 24 5.0
Sequin, TX 27 13.8 13 13.3 40 13.7 46 14.6 20 12.2 66 13.8
Tuscaloosa, AL 12 6.2 6 6.1 18 6.1 18 5.7 13 7.9 31 6.5
Baton Rouge, LA 14 7.2 7 7.1 21 7.2 21 6.7 11 6.7 32 6.7
Riverside, CA 11 5.6 5 5.1 16 5.5 17 5.4 8 4.9 25 5.2
Springﬁeld, MO 14  7.2 7 7.1 21 7.2 22 7.0 3 12.7 34 7.1
West  Palm Beach, FL 6 3.1 4 4.1 10 3.4 8 2.5 9 5.5 17 3.5
Battle Creek, MI  6 3.1 3 3.1 9 3.1 12 3.8 4 2.4 16 3.3
Metairie, LA 5 3.1 2 2.0 7 2.4 8 2.5 4 2.4 12 2.5
Baton Rouge, LA 3 1.5 2 2.0 5 1.7 6 1.9 5 3.0 11 2.3
Huntsville, AL 8 4.1 4 4.1 12 4.1 9 2.9 7 4.3 16 3.3
Sandy Springs, GA 1 0.5 0 0.0 1 0.3 1 0.3 0 0.0 1 0.2
Livonia, LA 19 9.7 11 11.2 30 10.2 31 9.8 22 13.4 53 11.1
Lawrence, KS 5 2.6 2 2.0 7 2.4 7 2.2 2 1.2 9 1.9
Memphis, TN 15 7.7 9 9.2 24 8.2 21 6.7 9 5.5 30 6.3
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Total  195 100 98 100 293 
hey were to be given by “pilling” (placing the tablet(s) at the back
f the mouth and gently holding the mouth shut until the dog swal-
owed). If a tablet was broken during chewing or if pieces of a tablet
ell from the dog’s mouth during chewing, the owner was  to recover
nd re-offer or re-dose the tablet or pieces of the tablet. In the case
f vomiting, the dog was to be re-dosed as soon as possible. Within
pproximately two days of dispensing treatment, unmasked study
ersonnel at the clinic contacted the owner to ensure treatment
as administered and determine if any adverse events had been
oted.
Primary dogs were returned to the clinic for ﬂea (tick) counts
nd an assessment for FAD on Day 14 ± 5 days. Subsequently, all
ogs were presented to the clinics on Days 30, 60 and 90; all vis-
ts had an allowable window of ±5 days. Primary dogs had ﬂea
nd tick counts and FAD assessments performed on each visit. All
ogs were weighed, and had a physical examination to assess gen-
ral health at each visit. On each of Days 30 and 60, owners were
ispensed the appropriate tablets to be dosed in the home environ-
ent as described above. On Day 90, all dogs had blood and urine
ollected for hematology, blood chemistry and urinalysis. Any dogs
resented for an unscheduled visit during the study were examined
y the study veterinarian for any abnormal health issues.
.3. Data analysis
For dogs withdrawn prior to the ﬁnal day of the study, efﬁ-
acy data up to the time of removal were included in statistical
ummaries and analyses. Live ﬂea counts were summarized with
eometric and arithmetic means by treatment group and time
oint. Percent effectiveness of each treated group was  calcu-
ated at each time point using the formula [(C − T)/C] × 100, where
 = pretreatment geometric mean ﬂea count and T = post-treatment
eometric mean ﬂea count.
The percentage reduction was calculated for each dog at each
ost-treatment time point, using the above formula, and if the per-
entage reduction for a dog was ≥90%, then the treatment was
onsidered a success for that dog. The ≥90% efﬁcacy level was  cho-
en based on regulatory requirements.
Exact 95% conﬁdence limits for the difference in treatment suc-
ess rates were constructed using the PROC BINOMIAL procedure in2.0 5 1.6 2 1.2 7 1.5
100 315 100 164 100 479 100
SAS (V9.3) from the StatXact (V10.0) PROCs package. The exact con-
ﬁdence intervals were constructed using the method described in
Agresti and Min  (2001) which utilizes a score statistic calculated as
the observed difference of the two binomial response rates minus
the hypothesized value, divided by the standard error. The lower
conﬁdence limit of the difference was used to test the hypothe-
ses of non-inferiority of sarolaner to spinosad and of superiority of
sarolaner to spinosad at the one-sided 0.025 level of signiﬁcance.
The impact of treatment on the clinical signs associated with
FAD was determined only for those dogs diagnosed with the
disease; for each of the clinical signs assessed the number and per-
centage of dogs with the sign were calculated for each assessment
day. These data were summarized, but not analyzed statistically, as
dogs were not randomly allocated to treatment based on clinical
signs.
3. Results
3.1. Demographics
A total of 479 client-owned dogs from 19 clinics in multiple geo-
graphic locations throughout the US were enrolled and included
in safety evaluations (Table 1). Treatment assignment resulted in
315 dogs receiving sarolaner and 164 dogs spinosad. Of these, 293
(195 sarolaner and 98 spinosad) were primary dogs included in
efﬁcacy evaluations. Of the total dogs, 242 (50.5%) were males and
237 (49.5%) were females. The number of intact and neutered dogs
was approximately the same in each group. The mean age of the
enrolled dogs was  5.0 ± 3.55 years (range 8 weeks–18.2 years).
Purebred dogs comprised 58.5% of the enrolled population with
Labrador Retrievers (7.7%), Chihuahuas (6.3%) and Shih Tzus (4.2%)
being enrolled most frequently. Additional population characteris-
tics for primary dogs (hair length, living conditions, and number of
other animals in the household) were also similarly represented in
the two  treatment groups (Table 2).
A total of 45 dogs were withdrawn from the study prior to
the ﬁnal study day. The most frequent reason for withdrawal was
owner-noncompliance with the protocol requirements (16 dogs).
Eleven dogs were withdrawn due to a change in ownership or
status (e.g., dog given away, missing, elective euthanasia or trau-
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Table 2
Demographics of primary dogs enrolled in a clinical ﬁeld study to investigate the
efﬁcacy and safety of sarolaner tablets administered orally once a month for three
months for the treatment and control of ﬂeas in dogs presented as veterinary
patients in the USA.
Sarolaner(n = 195) Spinosad(n = 98)
Hair length
Short 106 (54.4%) 50 (51.0%)
Medium 66 (33.8%) 40 (40.8%)
Long 23 (11.8%) 8 (8.2%)
Living conditionsa
Indoors and outdoors 76 (39.2%) 42 (42.9%)
Primarily indoors 90 (46.4%) 42 (42.9%)
Primarily outdoors 28 (14.4%) 14 (14.3%)
Other dogs or cats in household 120 (61.5%) 56 (57.1%)
Total dogs in household
1 101 (51.8%) 50 (51.0%)
2  68 (34.9%) 30 (30.6%)
3  26 (13.3%) 18 (18.4%)
Total cats in household
0 134 (68.7%) 74 (75.5%)
1  33 (16.9%) 13 (13.3%)
2  18 (9.2%) 7 (7.1%)
≥3 10 (5.1%) 4 (4.1%)
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a Living condition not reported for one sarolaner-treated dog.
atic death), six at the discretion of the owner (e.g., owner no
onger able or willing to participate in the study), ﬁve due to the
ousehold being disqualiﬁed (e.g., use of prohibited treatment or
ddition/removal of dogs in the household), three due to adverse
vents, three due to failure to meet inclusion criteria, and one due
o a dispensing error. Thus, 289/315 dogs in the sarolaner group
91.7%) and 145/164 (88.4%) of dogs in the spinosad group com-
leted the study.
.2. Dose acceptance
Both treatments were generally well accepted. For the sarolaner
ablets, of a total of 884 dosings, 91.5% were accepted by free choice
rom hand or in food; only 8.5% of doses had to be pilled. For
ogs dosed with spinosad tablets, the respective percentages were
1.1%, and 18.9% of the 451 doses given.
.3. Parasite counts
At screening primary dogs had ﬂea counts ranging from 10 to
513 (Table 3). Mean counts (arithmetic and geometric) were sim-
lar for dogs from the two treatment groups (Tables 3 and 4). Both
reatments resulted in large reductions in the numbers of live ﬂeas
ecovered at subsequent visits with mean efﬁcacies greater than
0% from Day 14 (the ﬁrst efﬁcacy time point). Treatment with
arolaner appeared to have a markedly greater effect on Days 14
nd 30 than spinosad (maximum ﬂea counts of ∼20 for sarolaner
s. ∼160 for spinosad) (Table 3). Compared to the pre-treatment
ount on Day 0, geometric mean live ﬂea counts were reduced
n Days 14, 30, 60 and 90 by 99.3%, 99.5%, 99.9%, and 99.9% in
he sarolaner group, and by 97.5%, 95.1%, 99.4%, and 99.6% in the
pinosad group (Table 4). Treatment success rates (proportion of
ogs with ≥90% reduction) for the sarolaner-treated dogs were
uperior (97.7 and 98.3%) to those for spinosad-treated dogs (90.0
nd 69.0%) on Days 14 and 30, respectively, and non-inferior on
ays 60 and 90 (P ≤ 0.025) (Table 4).
Prior to treatment on Day 0, ticks were present on only three
arolaner-treated dogs, and on only a single spinosad-treated dog.
herefore, too few dogs were infested with ticks to make any mean-
ngful conclusions with regards to efﬁcacy against ticks.sitology 222 (2016) 43–48
3.4. Clinical signs associated with FAD
Based on medical history and improvement in clinical signs
over the course of study treatment, 53 of the sarolaner-treated
dogs and 25 of spinosad-treated dogs were diagnosed as likely
to have FAD. Clinical signs associated with FAD improved over
the course of treatment in these dogs. Prior to the ﬁrst treat-
ment, sarolaner-treated dogs had clinical signs of pruritus (88.7%),
papules (49.9%), erythema (96.2%), scaling (67.9%), alopecia from
self-trauma (69.8%), and dermatitis/pyodermatitis (69.8%). Reduc-
tions in these clinical signs were seen within 14 days of the ﬁrst
treatment (Table 5). On Day 90, these percentages had improved
with sarolaner-treated dogs showing markedly lower incidences
of FAD clinical signs: pruritus (9.4%), papules (1.9%), erythema
(13.2%), scaling (15.1%), alopecia from self-trauma (7.5%), and der-
matitis/pyodermatitis (5.7%) (Table 5). Improvement was  similar in
the spinosad group.
3.5. Health observations
There were no treatment-related adverse events in sarolaner-
treated dogs. The majority of observed clinical signs were
consistent with allergies and dermatitis or sporadic occurrences
of conditions commonly observed in the general dog population.
Abnormal clinical signs occurring in >2.0% of sarolaner-treated dogs
included erythema (3.5%), pruritus (3.5%), emesis (3.2%), ear dis-
charge (2.5%), lethargy (2.5%), and cough (2.2%); incidences of these
signs were similar or higher in spinosad-treated dogs (Table 6).
Severe adverse events occurred in six dogs during the study. In
the sarolaner group one dog experienced worsening of preexisting
renal disease, one dog experienced sudden death from dilated car-
diomyopathy, and one dog was  found dead after an apparent animal
attack. In the spinosad group two dogs died as a result of road traf-
ﬁc accidents, and one dog was  euthanized because of deteriorating
health.
Mean results for hematology and serum chemistry in both treat-
ment groups were within the normal reference range and results
of urinalyses were also unremarkable in both treatment groups.
A wide variety of concomitant medications and therapies were
administered to dogs enrolled in this study and all appeared to
be well tolerated. The products administered most frequently to
dogs in both treatment groups were rabies vaccines (∼40% of dogs),
heartworm preventative (∼26% of dogs) and Bordetella vaccines
(∼12% of dogs).
4. Discussion
Four hundred and seventy-nine (479) dogs from different
regions of the US and broadly representative of the general dog
population were included in this study. For primary efﬁcacy dogs,
sarolaner chewable tablets administered orally once a month for
three months at a minimum dosage of 2.0 mg/kg (range 2–4 mg/kg)
were highly effective for the treatment and prevention of ﬂea
infestations. Geometric mean live ﬂea counts for these dogs were
reduced by >99% at 14 days after the ﬁrst treatment and contin-
ued to reduce through the study. This reduction in ﬂea infestation
was numerically greater than that for the comparator spinosad
tablets which resulted in only 97.5% reduction on Day 14 and
95.1% on Day 30, and only reached >99% after the second and third
treatments. Efﬁcacy based on the number of dogs with ≥90% reduc-
tion in ﬂeas was  statistically superior for sarolaner compared with
spinosad (P ≤ 0.025) on Days 14 and 30 (97.7 vs. 90.0% and 98.3 vs.
69.0%, respectively). Efﬁcacy following the second and third treat-
ments was similar for the two products. Thus, the excellent efﬁcacy
of sarolaner against ﬂea infestations previously demonstrated in
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Table  3
Number of dogs, arithmetic mean live ﬂea counts, ranges and percent efﬁcacies relative to pre-treatment counts for dogs presented as veterinary patients and dosed orally
with  sarolaner or spinosad tablets once a month for three months.
Count daya Sarolaner (2–4 mg/kg) Spinosad (≥30 mg/kg)
n Mean Range % Efﬁcacy n Mean Range % Efﬁcacy
0 186 110.1 10–1513 – 94 96.7 10–1127 –
14  177 1.0 0–24 99.1 90 5.2 0–168 94.6
30  176 0.6 0–20 99.5 87 9.2 0–161 90.5
60  161 0.1 0–2 99.9 83 0.5 0–7 99.5
90  156 <0.1 0–2 >99.9 77 1.2 0–58 98.8
a Day 0 = pre-treatment count, all other days ±5.
Table 4
Geometric mean live ﬂea counts and percent efﬁcacies relative to pre-treatment counts, the percentages of dogs considered treatment successes (≥90% reduction relative
to  pre-treatment), 95% conﬁdence limits for the difference in treatment success rates, and the hypothesis testing for dogs presented as veterinary patients and dosed orally
with  sarolaner or spinosad tablets once a month for three months.
Count daya Sarolaner (2–4 mg/kg) Spinosad (≥30 mg/kg) 95% conﬁdence limits for difference in% Success Hypothesis testing
Mean % Efﬁcacy % Successb Mean % Efﬁcacy % Successb NIc Sup.d
0 48.4 – – 47.8 – – – – –
14  0.4 99.3 97.7 1.2 97.5 90.0 (1.5, 16) * *
30  0.3 99.5 98.3 2.3 95.1 69.0 (20.1, 40.0) * *
60  <0.1 >99.9 100 0.3 99.4 100 (−2.3, 4.7) *
90  <0.1 >99.9 99.4 0.2 99.6 97.5 (−1.3, 8.7) *
a Day 0 = pre-treatment count, all other days ±5.
b % success is the proportion of dogs with ≥90% reduction relative to pre-treatment.
c Non-inferiority (NI)—sarolaner% success was non-inferior to that of spinosad for a 15% equivalence margin if the exact lower 95% conﬁdence limit ≥15%. “*” indicates
statistical signiﬁcance at the one-sided 0.025 signiﬁcance level.
d Superiority (Sup.)—sarolaner% success was signiﬁcantly greater than spinosad if the exact lower 95% conﬁdence limit of difference in proportions was >0%. “*” indicates
statistical signiﬁcance at the one-sided 0.025 signiﬁcance level.
Table 5
Percentage of ﬂea allergic dermatitis dogs with clinical signs by study day for dogs presented as veterinary patients and dosed orally with sarolaner or spinosad tablets once
a  month for three months.
Assessment daya n Pruritus Papules Erythema Scaling Alopecia from self-trauma Dermatitis/pododermatitis
Sarolaner (2–4 mg/kg) 0 53 88.7% 49.9% 96.2% 67.9% 69.8% 69.8%
14  53 47.2% 22.6% 56.6% 49.1% 39.6% 47.2%
30  53 32.0% 15.1% 30.2% 39.6% 35.8% 22.6%
60  52 8.0% 0.6% 26.9% 23.1% 17.3% 7.7%
90  53 9.4% 1.9% 13.2% 15.1% 7.5% 5.7%
Spinosad (≥30 mg/kg) 0 25 88.0% 40.0% 88.0% 72.0% 68.0 72.0%
14  24 41.7% 12.5% 41.7% 50.0% 45.8% 37.5%
30  25 32.0% 12.0% 32.0% 36.0% 40.0% 20.0%
60  25 8.0% 8.0% 16.0% 32.0% 16.0% 8.0%
90  25 8.0% 8.0% 12.0% 20.0% 20.0% 8.0%
a Day 0 = pre-treatment, all other days ±5.
Table 6
Incidences of abnormal clinical signs occurring in >2% of sarolaner-treated dogs presented as veterinary patients and dosed orally with sarolaner or spinosad tablets once a
month  for three months.
Clinical sign Sarolaner (2–4 mg/kg) (n = 315) Spinosad (≥30 mg/kg) (n = 164)
n % n %
Erythema 11 3.5% 5 3.0%
Pruritus 11 3.5% 12 7.3%
Emesis 10 3.2% 16 9.8%
Ear  Discharge 8 2.5% 2 1.2%
Lethargy 8 2.5% 3 1.2%
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aboratory studies (Six et al., 2016a,b) was conﬁrmed under typ-
cal use conditions in the general dog population with treatment
dministered by the owner. The rapid reduction of the levels of
ea infestation in these dogs reﬂects the rapid onset of activity of
arolaner that was demonstrated in speed of kill studies (Six et al.,
016b), and the fact that ﬂeas are likely killed before they have the
hance to lay eggs (Six et al., 2016a; Dryden et al., 2007). These com-
ined effects resulted in the reduction in the ﬂea populations in the5 3.0%
dogs’ environments by rapidly killing newly emerged ﬂeas on the
dogs before they had the chance to lay eggs and contribute to the
environmental re-infestation. The reduction of over 99% within 14
days of the ﬁrst treatment is consistent with the results obtained
in a simulated-home, ﬂea-infested environment study (Six et al.,
2016a).
The rapid reduction in ﬂea infestations provided by treatment
with sarolaner tablets resulted in a similar rapid resolution of the
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(SimparicaTM) against ﬂeas on dogs. Vet. Parasitol. (This Edition).
Six, R.H., Geurden, T., Packianathan, R., Colgan, S., Everett, W.R., Grace, S., Hodge, A.,
Mahabir, S.P., Myers, M.R., Slootmans, N., Davis, K., 2016b. Evaluation of the
effectiveness of a novel oral formulation of sarolaner for the treatment and
control of ﬂeas on dogs. Vet. Parasitol. (This Edition).8 J.A. Cherni et al. / Veterinar
linical signs commonly seen in dogs diagnosed with FAD. Prior to
he initial treatment, nearly 90% of the sarolaner group dogs had
ruritus, the most common sign associated with ﬂea allergy, and
his dropped to only 9% of dogs by the end of the study.
Sarolaner tablets were well accepted with the majority of offer-
ngs (91.5%) taken by free choice from the hand or in food and
nly 8.5% of tablets required pilling, while almost 20% of the chew-
ble comparator tablets were pilled. This demonstrates that the
arolaner tablet formulation is palatable to the majority of dogs
nd should prove easy and convenient for owners to dose under
ormal use conditions.
Sarolaner tablets were well-tolerated. The majority of signs
eported were those consistent with allergies and dermatitis, or
poradic occurrences of conditions in the general dog popula-
ion, such as emesis and pruritus. These latter two signs were
ore common in the spinosad-treated comparator group (9.8% and
.3%, respectively). Three severe adverse events occurred in each
reatment group but none was considered to be related to either
reatment. These were either worsening of a pre-existing condition,
ccidental injury or death, or an acute death due to cardiomyopa-
hy. For both treatment groups, clinical pathology ﬁndings were
nremarkable, and the various concomitant medications such as
accines, anthelmintics, heartworm preventatives, antibiotics, and
teroids that were administered during the study were well toler-
ted.
. Conclusions
Under the conditions of this study, sarolaner ﬂavored, chewable
ablets (SimparicaTM) administered orally to provide a minimum
osage of 2.0 mg/kg (range 2–4 mg/kg) once monthly for three
onsecutive treatments was highly effective in the treatment and
revention of natural infestations of ﬂeas. Sarolaner resulted in a
ubstantial improvement of all clinical signs associated with FAD
nd was readily accepted free choice by most dogs. Sarolaner was
ell tolerated by dogs and will be an important advance in the
ffective treatment and control of ﬂeas on dogs.
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